Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand.
Rheumatology Division, Department of Internal Medicine, Padjadjaran University, Bandung, Indonesia.
Int J Rheum Dis. 2022 Nov;25(11):1220-1229. doi: 10.1111/1756-185X.14413. Epub 2022 Aug 2.
The prevalence of systemic lupus erythematosus (SLE) is higher in Asians than Caucasians, with higher frequency of renal and other major organ manifestations that carry a poorer prognosis. The outcome of SLE is still unsatisfactory in many parts of the Asia Pacific region due to limited access to healthcare systems, poor treatment adherence and adverse reactions to therapies. The Asia Pacific League of Associations for Rheumatology (APLAR) SLE special interest group has recently published a set of consensus recommendation statements for the management of SLE in the Asia Pacific region. The current article is a supplement of systematic literature search (SLR) to the prevalence and treatment of non-renal manifestations of SLE in Asian patients.
系统性红斑狼疮（SLE）在亚洲人群中的发病率高于白种人，亚洲人群的肾脏和其他重要器官表现更为常见，预后更差。由于医疗保健系统的可及性有限、治疗依从性差以及对治疗的不良反应，亚太地区许多地方的 SLE 治疗效果仍不尽人意。亚太风湿病学会联盟（APLAR）SLE 特别兴趣小组最近发布了一套亚太地区 SLE 管理共识推荐声明。本文是对亚洲患者 SLE 非肾脏表现的患病率和治疗的系统文献检索（SLR）的补充。
